Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.

PURPOSE Activation of transcription factor nuclear factor-kappaB (NF-kappaB) has been shown to play a role in cell proliferation, apoptosis, cytokine production, and oncogenesis. The purpose of this study was to determine whether NF-kappaB is constitutively activated in human gastric carcinoma tissues and, if so, to determine any correlation between NF-kappaB activity and clinicopathological features of gastric carcinoma. EXPERIMENTAL DESIGN NF-kappaB activation was determined by immunohistochemical analysis of formalin-fixed, paraffin-embedded specimens from 64 gastric carcinoma patients. We quantified nuclear staining of RelA as a marker of NF-kappaB activation. RESULTS Nuclear translocation of RelA was significantly high in tumor cells in comparison to that in adjacent normal epithelial cells (22.5 +/- 2.4% versus 8.6 +/- 1.5%, P < 0.0001). There was a significant correlation between NF-kappaB activation (nuclear translocation of RelA) and expression of urokinase-type plasminogen activator, an invasion-related factor and target of NF-kappaB in tumor cells (rho = 0.393; P = 0.0013). NF-kappaB activation was correlated with tumor invasion-related clinicopathological features such as lymphatic invasion of tumor cells (P = 0.0126), depth of invasion (P = 0.0539), peritoneal metastases (P = 0.0538), and tumor size (P = 0.0164). CONCLUSIONS Collectively, the data show that NF-kappaB is constitutively activated in human gastric carcinoma tissues and suggest that NF-kappaB activity is related to tumor progression due to its transcriptional regulation of invasion-related factors such as urokinase-type plasminogen activator.

[1]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[2]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[3]  J. Roth,et al.  Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. , 1995, Oncogene.

[4]  M. P. Miano,et al.  Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression , 1997, Oncogene.

[5]  K. Albermann,et al.  Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review) , 1992 .

[6]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[7]  N. Shimizu,et al.  Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression. , 1999, Human gene therapy.

[8]  G. Franzoso,et al.  Structure, regulation and function of NF-kappa B. , 1994, Annual review of cell biology.

[9]  A. Richmond,et al.  Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells , 1997 .

[10]  R. Medzhitov,et al.  The Toll-receptor family and control of innate immunity. , 1999, Current opinion in immunology.

[11]  R. Corley,et al.  Constitutive Nuclear Translocation of NF-κB in B Cells in the Absence of IκB Degradation , 1999, The Journal of Immunology.

[12]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[13]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[14]  E. Lengyel,et al.  Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor* , 1999, The Journal of Biological Chemistry.

[15]  P. Rørth,et al.  Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. , 1991, Oncogene.

[16]  N. Fausto,et al.  Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  M. Karin,et al.  Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B , 1995, Molecular and cellular biology.

[18]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[19]  A. Ford-hutchinson,et al.  Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.

[20]  G. Sonenshein.  Rel/NF-κB transcription factors and the control of apoptosis , 1997 .

[21]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[22]  T. Ichikura,et al.  Prognostic impact of stromal cell‐derived urokinase–type plasminogen activator in gastric carcinoma , 1999, Cancer.

[23]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[24]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[25]  M. Schmitt,et al.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. , 1995, Nucleic acids research.

[26]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[27]  V. Castronovo,et al.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. , 1994, Biochemical pharmacology.

[28]  E. Lengyel,et al.  Regulation of urokinase‐type plasminogen activator expression by an ERK1‐dependent signaling pathway in a squamous cell carcinoma cell line , 1996, Journal of cellular biochemistry.

[29]  Douglas B. Evans,et al.  Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA , 1999, Oncogene.

[30]  M. Schmitt,et al.  Inhibition of NF-KB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAl-1 , 1995 .

[31]  M. Rugge,et al.  Cysteine and serine proteases in gastric cancer , 1995, Cancer.

[32]  H. Allgayer,et al.  Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Altorki,et al.  Defining the invasive phenotype of proximal gastric cancer cells , 1994, Cancer.

[34]  K. Becker,et al.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. , 1994, Cancer research.

[35]  F. A. La Rosa,et al.  Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors , 1994, Molecular and cellular biology.

[36]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[37]  H. Nakshatri,et al.  NF-κB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1α , 1998 .

[38]  U. Zabel,et al.  Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. , 1993, The EMBO journal.

[39]  B. Aggarwal,et al.  Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. , 1998, The Journal of biological chemistry.